CIV

Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Thursday, April 25, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, FDA, Research, Webcast, Prescription, ODD, NEST, European Medicines Agency, Deficit spending, PAM, MCI, Innovation, Hearing, Woman, PBM, Cognition, CIV, MHRA, Therapy, Plasma, Tremor, Safety, Insurance, Natural history, HD, Incidence, EMA, Government, Sale, Essential tremor, PPD, NMDA, Health care, GABAA, Patient, Pharmaceutical industry

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2024.
  • In the first quarter of 2024, OBGYNs accounted for the largest share of prescriptions, followed by psychiatrists and PCPs.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $6.2 million in the first quarter of 2024, the first full quarter of sales.
  • ET to review its first quarter 2024 financial results and discuss recent corporate updates.

Ice Wine, Vernaccia di Oristano, Barolo, Cerasuolo d'Abruzzo, and Lambrusco secure top honors in the prestigious 5StarWines & Wine Without Walls Selection at Vinitaly

Retrieved on: 
Thursday, April 11, 2024
Wine, Master class, Selection, Trophy, CIV, Banco BPM

VERONA, Italy, April 11, 2024 /PRNewswire-PRWeb/ -- The 2024 edition of 5StarWines & Wine Without Walls drew to a close a few hours ago, after three days of blind tastings by an international panel of judges. While waiting for the list of the 884 selected wines of 5StarWines & Wine Without Walls to be announced, here are the names of the wines and wineries that were awarded the 20 special Trophies.                 

Key Points: 
  • 5StarWines & Wine Without Walls, the prestigious annual wine selection event held for its 8th edition in Verona from 9-11 April, has announced a selection of 884 wines and 20 Trophy winners for this year's event.
  • For the "green" section of the Selection, the winery selected for top honors is Fattoria La Vialla di Gianni, Antonio e Bandino Lo Franco.
  • VERONA, Italy, April 11, 2024 /PRNewswire-PRWeb/ -- The 2024 edition of 5StarWines & Wine Without Walls drew to a close a few hours ago, after three days of blind tastings by an international panel of judges.
  • Over 2300 wines participated in Veronafiere's tasting event, one of the most prestigious wine selections in Italy.

IHS Holding Limited Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 12, 2024
Technology, Telecommunications, IHS, Loan, Approximation, Standard Chartered, SSA, IHS Towers, GTS, Movement, MTN, Nigerian naira, MENA, ZAR, CIV, FX, USD, NGN

Revenue for our Nigeria segment decreased by $34.6 million, or 9.7%, to $320.7 million for the fourth quarter of 2023, compared to $355.3 million for the fourth quarter of 2022.

Key Points: 
  • Revenue for our Nigeria segment decreased by $34.6 million, or 9.7%, to $320.7 million for the fourth quarter of 2023, compared to $355.3 million for the fourth quarter of 2022.
  • Revenue for our Latam segment increased by $10.4 million, or 23.8%, to $54.3 million for the fourth quarter of 2023, compared to $43.9 million for the fourth quarter of 2022.
  • During the fourth quarter of 2023, capital expenditure (“Total Capex”) was $130.6 million, compared to $195.6 million for the fourth quarter of 2022.
  • The loan is guaranteed by IHS Netherlands Holdco B.V., IHS Netherlands NG1 B.V., IHS Towers NG Limited, IHS Netherlands NG2 B.V., Nigeria Tower Interco B.V., INT Towers Limited and IHS Nigeria.

Goldhirsh Foundation Names Groundbreaking All-Female Investment Committee

Retrieved on: 
Thursday, March 14, 2024
Cream, Boston University, AB, City, NationBuilder, TCE, UCLA, CIO, HEC Paris, Bookshop (company), Harvard University, BBDO, Wilshire Associates, Brown University, Woman, CFA, Committee on Finance, SpaceX, Larchmont Charter School, Saatchi & Saatchi, Organization, Eric Schmidt, Chopped, Planet Labs, Acquisition, University, Food, ASTR, American Dream, M13, LOS, The arts, School, Samuel Adams, MBA, Coolhaus, YPO, Zagat, CIV, Shana, Partner, Collaborative Fund

LOS ANGELES, March 14, 2024 /PRNewswire/ -- Today, the Goldhirsh Foundation announced its new all-female investment committee—believed to be the first such investment committee at an organization of its size and scope. The committee members are: Shana Barghouti, Natasha Case, Celestine Schnugg, and Ruth Wernig.

Key Points: 
  • This new, all-female, investment committee is believed to be the first such at an organization of this size and scope.
  • "All four women on our new investment committee have proven themselves as business and civic leaders, as well as visionaries, during the course of their careers," said Tara Roth, President of the Goldhirsh Foundation.
  • The new committee – with the experience, network, and expertise they bring – further solidifies a strategic shift for the Goldhirsh Foundation's endowment.
  • Meet the members of the Goldhirsh Foundation investment committee:
    Shana Barghouti, Co-Chief Investment Officer at ReMY Investors, a multi-family investment firm based in Los Angeles.

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Wednesday, February 14, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, PD, Research, Sale, Tremor, Health care, NMDA, Innovation, Webcast, Plasma, Incidence, GABAA, CIV, Standard of care, Deficit spending, Therapy, European Medicines Agency, Food and Drug Administration, MCI, NEST, HCP, Woman, Schedule, USAN, Postpartum depression, ODD, Safety, Prescription, Insurance, EMA, FDA, Food, Passport, DEA, PAM, DSM-IV codes, Risk, PPD, Patient, MHRA, Cognition, Essential tremor, Pharmaceutical industry

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $0.8 million in the fourth quarter of 2023, the first quarter of sales.
  • Net Loss: Net loss was $32.7 million for the fourth quarter of 2023 compared to $147.1 million for the same period in 2022.
  • ET to review its fourth quarter and full year 2023 financial results and discuss recent corporate updates.

RTX's Raytheon business awarded $154 million to deliver Commander's Independent Viewer units to the U.S. Army

Retrieved on: 
Wednesday, January 24, 2024
Bradley Fighting Vehicle, CIV, Commander, FLIR

"The CIV is a package of multiple systems all working together to increase the survivability and battlefield performance of the Bradley Fighting Vehicle," said Bryan Rosselli, president of Advanced Products and Solutions at Raytheon. "These capabilities -- early threat detection, 360-degree battlefield view, and all-weather performance -- increase a vehicle commander's ability to locate, identify and defeat stationary and moving targets in any condition – day or night."

Key Points: 
  • System upgrades battlefield oversight and target hand-off capabilities to the U.S. Army's Bradley Fighting Vehicle
    MCKINNEY, Texas, Jan. 24, 2024 /PRNewswire/ -- Raytheon, an RTX (NYSE: RTX) business, announced a $154 million award to deliver Commander's Independent Viewer (CIV) systems to the U.S. Army to upgrade the service's Bradley Fighting Vehicles.
  • CIV is an electro-optical/infrared sight system utilizing second-generation forward-looking infrared (FLIR) cameras and sensors that provide the U.S. Army's Bradley Fighting Vehicle with 360-degree battlefield oversight and targeting capabilities.
  • "The CIV is a package of multiple systems all working together to increase the survivability and battlefield performance of the Bradley Fighting Vehicle," said Bryan Rosselli, president of Advanced Products and Solutions at Raytheon.
  • The first two generations of Raytheon's FLIR technology have served forces for more than half a century.

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023
Walking, Pregnancy, Theft, PPD, Risk, Vitamin, Benzodiazepine, Breast milk, Tell, CIV, Woman, Grammatical mood, OBGYN, Medical research, Hope, Biogen, Capsule, BIIB, Health, Physician, Alertness, Sage, Therapy, Dizziness, Mental health, Behavior, Insurance, Confusion, CNS, Pharmacy, Medicaid, Patient, Diagnosis, Central nervous system, Somnolence, Pharmaceutical industry

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced ZURZUVAE™ (zuranolone) 50 mg (two 25 mg capsules per day) CIV is now available by prescription for the treatment of postpartum depression (PPD) for adults in the United States, with product already at specialty pharmacies and delivered to patients. ZURZUVAE is the first and only oral, 14-day treatment course for adults with PPD that can provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3.

Key Points: 
  • “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023
Health, FDA, Consumer, Women, Clinical Trials, Pharmaceutical, Biotechnology, CNS, Capsule, Woman, Tell, Medicaid, Behavior, Hope, Therapy, Breast milk, Grammatical mood, Physician, Risk, New America (organization), Patient, Multimedia, Insurance, Pregnancy, CIV, Theft, Medical research, Benzodiazepine, Vitamin, Diagnosis, BIIB, PPD, Mental health, Central nervous system, Alertness, Confusion, Walking, Somnolence, OBGYN, Dizziness, Pharmacy, Dietary supplement, Pharmaceutical industry, Nursing, Birth control, Liquor, Gasoline, Health insurance, Hospital, Sage, Biogen

View the full release here: https://www.businesswire.com/news/home/20231213368658/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231213368658/en/
    “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?

NEURELIS ANNOUNCES PRESENTATIONS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

Retrieved on: 
Friday, December 1, 2023
Empowerment, Status epilepticus, Brain, Research, Annual general meeting, Additive effect, SAN, Food, American Epilepsy Society, Effectiveness, Panic, Literature, Plasma, Risk, Comparison, AAS, CIV, Diazepam, FDA, Prompt, Pharmacokinetics, Caregiver, Epilepsy, Human, DZP, Rat, Systematic review, AES, Pharmaceutical industry, Drug, Vaccine, Dietary supplement, Seizure, Male, Patient, Female, Safety

SAN DIEGO, Dec. 1, 2023 /PRNewswire/ -- Neurelis, Inc., today announced that the company will present six poster presentations at the American Epilepsy Society (AES) Annual Meeting held in Orlando, Florida from December 1 – 5, 2023. Two of the presentations include new analyses of data from the completed long-term phase 3 open-label, repeat-dose safety study of diazepam nasal spray (VALTOCO®) for the treatment of seizure clusters in patients with epilepsy aged ≥6 years, evaluating timing, safety, and effectiveness of treatment. A third presentation focuses on the further assessment of diazepam in a novel preclinical model dosing strategy with potential application for further in vivo studies. Additional presentations explore the concept of anticipatory anxiety of seizures (AAS) through literature review, comparison of treated and untreated seizure clusters in a retrospective analysis from the SeizureTracker® database, and the short-term impact of seizures beyond the seizure itself.

Key Points: 
  • "Our ultimate goal is to improve health outcomes by addressing gaps in seizure cluster treatment and control," said Adrian L. Rabinowicz, M.D., Chief Medical Officer.
  • "The data presented this year at the AES annual meeting demonstrate our ongoing commitment to improving the future of epilepsy care by advancing meaningful, patient-focused treatment outcomes for people with epilepsy."
  • "Neurelis is at the forefront of epilepsy research, as evidenced by the wide breadth of data presented at this year's AES annual meeting," said Enrique Carrazana, M.D., Neurelis Senior Vice President, Strategic Initiatives.
  • Results showed sustained and measurable DZP levels in plasma and brain, which were similar to levels observed in humans.

Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Tuesday, November 7, 2023
Research, Mental Health, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Woman, AD, PD, Food, MCI, DSM-IV codes, European Medicines Agency, Deficit spending, CIV, GABAA, Risk, Schedule, Sale, Essential tremor, MDD, HD, Workforce, DEA, Acquisition, Webcast, EMA, Safety, Therapy, Patient, D, PPD, Plasma, Tremor, ODD, Zuranolone, Education, Incidence, PAM, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NMDA, Diagnosis, Grammatical mood, Nursing, Pharmaceutical industry, Dietary supplement, Surveying, Elevator mechanic, Biogen, Sage

Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported business highlights and financial results for the third quarter ended September 30, 2023.
  • ZURZUVAE is being developed and commercialized in collaboration with Biogen Inc. Sage also commercializes ZULRESSO® (brexanolone) CIV injection in the treatment of PPD.
  • Restructuring Expenses: Restructuring expenses were $33.6 million in the third quarter of 2023 due to the August 2023 corporate reorganization.
  • ET to review its third quarter 2023 financial results and discuss recent corporate updates.